Clinical Trial Update: Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating recombinant surfactant protein D (rfhSP-D) to prevent chronic lung disease in premature infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia
• Lung Disease of Prematurity
• Respiratory Distress Syndrome

Drugs mentioned

• Recombinant Surfactant Protein D (rfhSP-D) (rfhSP-D)

Snippet

Sponsor: University College, London | Conditions: Chronic Lung Disease of Prematurity, Respiratory Distress Syndrome in Premature Infant | Phase 1 | Status: COMPLETED